Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05200923

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

To collect physiological signals at several timepoints during the therapy evaluation period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Indiana University Health Methodist Research Institute, Indianapolis, Indiana, United States

Loading trial locations.

About this study

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this non-applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Overactive Bladder Criteria Inclusion Criteria

  • 18 years of age or older
  • Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  • Willing and able to provide signed and dated informed consent
  • Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  • Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation
  • For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.
  • For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Non-Obstructive Urinary Retention Inclusion Criteria

  • 18 years of age or older
  • Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  • Willing and able to provide signed and dated informed consent
  • Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  • Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation
  • Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Fecal Incontinence Inclusion Criteria

  • 18 years of age or older
  • Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation
  • Willing and able to provide signed and dated informed consent
  • Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  • Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation
  • Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling)

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Exclusion criteria

Overactive Bladder Criteria Exclusion Criteria

  • Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  • Implanted with a neurostimulator, pacemaker or defibrillator
  • Pelvic floor muscle dysfunction due to surgical intervention or injury
  • Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  • History of diabetes unless the diabetes is well-controlled through diet and/or medications
  • Have symptomatic urinary tract infection (UTI)
  • Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
  • Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
  • Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  • Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  • Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  • Women who are pregnant or planning to become pregnant
  • Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  • Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Non-Obstructive Urinary Retention Exclusion Criteria

  • Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  • Implanted with a neurostimulator, pacemaker or defibrillator
  • Pelvic floor muscle dysfunction due to surgical intervention or injury
  • Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  • History of diabetes unless the diabetes is well-controlled through diet and/or medications
  • Have symptomatic urinary tract infection (UTI)
  • Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  • Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  • Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  • Women who are pregnant or planning to become pregnant
  • Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  • Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Fecal Incontinence Exclusion Criteria

  • Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  • Implanted with a neurostimulator, pacemaker or defibrillator
  • Pelvic floor muscle dysfunction due to surgical intervention or injury
  • Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  • Have uncorrected high grade internal rectal prolapse
  • Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  • Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  • Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  • Women who are pregnant or planning to become pregnant
  • Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Treatment and study plan

Sacral Neuromodulation

Device

Sacral neuromodulation delivers electrical stimulation to a sacral nerve

Primary outcomes

  1. Number of subjects with physiological signals collected at each timepoint

    Time frame: 1 day to 7 months

    The proportion of subjects with evaluable signals will be summarized at each timepoint

Study contacts

Contact information is provided by the study sponsor or research team.

Katherine Peterson

CONTACT

[email protected]

414-704-4065

Sponsors and collaborators

Lead sponsor

MedtronicNeuro

Industry

Registry information

Acronym: PEER 2

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jan 21, 2022
Registry last updated
Mar 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.